Repeat polymorphisms in ESR2 and AR and colorectal cancer risk and prognosis: results from a German population-based case-control study

BMC Cancer

Anja Rudolph²  Hong Shi⁶  Asta Försti⁵  Michael Hoffmeister⁴  Juan Sainz¹  Lina Jansen⁴  Kari Hemminki⁵  Hermann Brenner³  Jenny Chang-Claude² 

[1] Pfizer - Universidad de Granada - Junta de Andalucía Centre for Genomics and Oncological Research (GENYO), Av de la Ilustración 114, 18007 Granada, Spain

[2] Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 581, 69120 Heidelberg, Germany

[3] German Cancer Consortium (DKTK), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany

[4] Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 581, 69120 Heidelberg, Germany

[5] Center for Primary Health Care Research, Clinical Research Center, Jan Waldenströms gata 35, SUS, 205 02 Malmö, Sweden

[6] Department of Oncology, Tangdu Hospital of Fourth Military Medical University, Changle West Rd, Xi’an 710032, People’s Republic of China

关键词: Short tandem repeat;    Genetic polymorphism;    Androgen receptor;    Estrogen receptor beta;    Colorectal cancer;   

Others  :  1120228
DOI  :  10.1186/1471-2407-14-817

 received in 2014-04-29, accepted in 2014-10-27,  发布年份 2014

【 摘 要 】

Background

Evidence has accumulated which suggests that sex steroids influence colorectal cancer development and progression. We therefore assessed the association of repeat polymorphisms in the estrogen receptor β gene (ESR2) and the androgen receptor gene (AR) with colorectal cancer risk and prognosis.

Methods

The ESR2 CA and AR CAG repeat polymorphisms were genotyped in 1798 cases (746 female, 1052 male) and 1810 controls (732 female, 1078 male), matched for sex, age and county of residence. Colorectal cancer risk associations overall and specific for gender were evaluated using multivariate logistic regression models adjusted for sex, county of residence and age. Associations with overall and disease-specific survival were evaluated using Cox proportional hazard models adjusted for established prognostic factors (diagnosis of other cancer after colorectal cancer diagnosis, detection by screening, treatment with adjuvant chemotherapy, tumour extent, nodal status, distant metastasis, body mass index, age at diagnosis and year of diagnosis) and stratified for grade of differentiation. Heterogeneity in gender specific associations was assessed by comparing models with and without a multiplicative interaction term by means of a likelihood ratio test.

Results

The average number of ESR2 CA repeats was associated with a small 5% increase in colorectal cancer risk (OR = 1.05, 95% CI 1.01-1.10) without significant heterogeneity according to gender or tumoural ESR2 expression. We found no indication for an association between the AR CAG repeat polymorphisms and risk of colorectal cancer. The ESR2 CA and AR CAG repeat polymorphisms were not associated with overall survival or disease specific survival after colorectal cancer diagnosis.

Conclusions

Higher numbers of ESR2 CA repeats are potentially associated with a small increase in colorectal cancer risk. Our study does not support an association between colorectal cancer prognosis and the investigated repeat polymorphisms.

【 授权许可】

   
2014 Rudolph et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Kennelly R, Kavanagh DO, Hogan AM, Winter DC: Oestrogen and the colon: potential mechanisms for cancer prevention. Lancet Oncol 2008, 9(4):385-391.
• [2]Koo JH, Leong RW: Sex differences in epidemiological, clinical and pathological characteristics of colorectal cancer. J Gastroenterol Hepatol 2010, 25(1):33-42.
• [3]Lin KJ, Cheung WY, Lai JY, Giovannucci EL: The effect of estrogen vs. combined estrogen-progestogen therapy on the risk of colorectal cancer. Int J Cancer 2012, 130(2):419-430.
• [4]Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R, Early Breast Cancer Trialists’ Collaborative Group (EBCTCG): Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011, 378(9793):771-784.
• [5]Catalano MG, Pfeffer U, Raineri M, Ferro P, Curto A, Capuzzi P, Corno F, Berta L, Fortunati N: Altered expression of androgen-receptor isoforms in human colon-cancer tissues. Int J Cancer 2000, 86(3):325-330.
• [6]Castagnetta L, Traina A, Campisi I, Calabro M, Maratta A, Saetta A, Agostara B, Mezzatesta N: Androgen receptor status in nontumoral and malignant human colorectal tissues. Ann N Y Acad Sci 2002, 963:322-325.
• [7]D’Errico I, Moschetta A: Nuclear receptors, intestinal architecture and colon cancer: an intriguing link. Cell Mol Life Sci 2008, 65(10):1523-1543.
• [8]Africander D, Verhoog N, Hapgood JP: Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception. Steroids 2011, 76(7):636-652.
• [9]Westberg L, Baghaei F, Rosmond R, Hellstrand M, Landen M, Jansson M, Holm G, Bjorntorp P, Eriksson E: Polymorphisms of the androgen receptor gene and the estrogen receptor beta gene are associated with androgen levels in women. J Clin Endocrinol Metab 2001, 86(6):2562-2568.
• [10]Peter I, Kelley-Hedgepeth A, Fox CS, Cupples LA, Huggins GS, Housman DE, Karas RH, Mendelsohn ME, Levy D, Murabito JM: Variation in estrogen-related genes associated with cardiovascular phenotypes and circulating estradiol, testosterone, and dehydroepiandrosterone sulfate levels. J Clin Endocrinol Metab 2008, 93(7):2779-2785.
• [11]Haring R, Ernst F, Schurmann C, Homuth G, Volker U, Volzke H, Nauck M, Wallaschofski H: The androgen receptor CAG repeat polymorphism as a risk factor of low serum testosterone and its cardiometabolic effects in men. Int J Androl 2012, 35(4):511-520.
• [12]Travison TG, Shackelton R, Araujo AB, Morley JE, Williams RE, Clark RV, McKinlay JB: Frailty, serum androgens, and the CAG repeat polymorphism: results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2010, 95(6):2746-2754.
• [13]Huhtaniemi IT, Pye SR, Limer KL, Thomson W, O’Neill TW, Platt H, Payne D, John SL, Jiang M, Boonen S, Borghs H, Vanderschueren D, Adams JE, Ward KA, Bartfai G, Casanueva F, Finn JD, Forti G, Giwercman A, Han TS, Kula K, Lean ME, Pendleton N, Punab M, Silman AJ, Wu FC, European Male Ageing Study Group: Increased estrogen rather than decreased androgen action is associated with longer androgen receptor CAG repeats. J Clin Endocrinol Metab 2009, 94(1):277-284.
• [14]Kazemi-Esfarjani P, Trifiro MA, Pinsky L: Evidence for a repressive function of the long polyglutamine tract in the human androgen receptor: possible pathogenetic relevance for the (CAG)n-expanded neuronopathies. Hum Mol Genet 1995, 4(4):523-527.
• [15]Beilin J, Ball EM, Favaloro JM, Zajac JD: Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: specificity in prostate and non-prostate cell lines. J Mol Endocrinol 2000, 25(1):85-96.
• [16]Slattery ML, Sweeney C, Murtaugh M, Ma KN, Wolff RK, Potter JD, Caan BJ, Samowitz W: Associations between ERalpha, ERbeta, and AR genotypes and colon and rectal cancer. Cancer Epidemiol Biomarkers Prev 2005, 14(12):2936-2942.
• [17]Gordon MA, Zhang W, Yang D, Iqbal S, El-Khouiery A, Nagashima F, Lurje G, Labonte M, Wilson P, Sherrod A, Ladner RD, Lenz HJ: Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin. Pharmacogenomics 2011, 12(1):27-39.
• [18]Press OA, Zhang W, Gordon MA, Yang D, Haiman CA, Azuma M, Iqbal S, Lenz HJ: Gender-related survival differences associated with polymorphic variants of estrogen receptor-beta (ERbeta) in patients with metastatic colon cancer. Pharmacogenomics J 2011, 11(5):375-382.
• [19]Rudolph A, Toth C, Hoffmeister M, Roth W, Herpel E, Jansen L, Marx A, Brenner H, Chang-Claude J: Expression of oestrogen receptor beta and prognosis of colorectal cancer. Br J Cancer 2012, 107(5):831-839.
• [20]Brenner H, Chang-Claude J, Seiler CM, Rickert A, Hoffmeister M: Protection from colorectal cancer after colonoscopy: a population-based, case-control study. Ann Intern Med 2011, 154(1):22-30.
• [21]Rudolph A, Sainz J, Hein R, Hoffmeister M, Frank B, Forsti A, Brenner H, Hemminki K, Chang-Claude J: Modification of menopausal hormone therapy associated colorectal cancer risk by polymorphisms in sex steroid signaling, metabolism and transport related genes. Endocr Relat Cancer 2011, 18(3):371-384.
• [22]Hoffmeister M, Raum E, Krtschil A, Chang-Claude J, Brenner H: No evidence for variation in colorectal cancer risk associated with different types of postmenopausal hormone therapy. Clin Pharmacol Ther 2009, 86(4):416-424.
• [23]Schemper M, Smith TL: A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996, 17(4):343-346.
• [24]Honma N, Arai T, Takubo K, Younes M, Tanaka N, Mieno MN, Tamura K, Ikeda S, Sawabe M, Muramatsu M: Oestrogen receptor-beta CA repeat polymorphism is associated with incidence of colorectal cancer among females. Histopathology 2011, 59(2):216-224.
• [25]Honma N, Yamamoto K, Ohnaka K, Morita M, Toyomura K, Kono S, Muramatsu M, Arai T, Ueki T, Tanaka M, Kakeji Y, Maehara Y, Okamura T, Ikejiri K, Futami K, Maekawa T, Yasunami Y, Takenaka K, Ichimiya H, Terasaka R: Estrogen receptor-beta gene polymorphism and colorectal cancer risk: effect modified by body mass index and isoflavone intake. Int J Cancer 2012, 132(4):951-958.
• [26]Passarelli MN, Phipps AI, Potter JD, Makar KW, Coghill AE, Wernli KJ, White E, Chan AT, Hutter CM, Peters U, Newcomb PA: Common single-nucleotide polymorphisms in the estrogen receptor beta promoter are associated with colorectal cancer survival in postmenopausal women. Cancer Res 2013, 73(2):767-775.
• [27]Fang YJ, Lu ZH, Wang F, Wu XJ, Li LR, Zhang LY, Pan ZZ, Wan DS: Prognostic impact of ERbeta and MMP7 expression on overall survival in colon cancer. Tumour Biol 2010, 31(6):651-658.
• [28]Gruber CJ, Tschugguel W, Schneeberger C, Huber JC: Production and actions of estrogens. N Engl J Med 2002, 346(5):340-352.
• [29]Cleveland AG, Oikarinen SI, Bynoté KK, Marttinen M, Rafter JJ, Gustafsson JA, Roy SK, Pitot HC, Korach KS, Lubahn DB, Mutanen M, Gould KA: Disruption of estrogen receptor signaling enhances intestinal neoplasia in Apc(Min/+) mice. Carcinogenesis 2009, 30(9):1581-1590.
• [30]Edvardsson K, Strom A, Jonsson P, Gustafsson JA, Williams C: Estrogen receptor beta induces antiinflammatory and antitumorigenic networks in colon cancer cells. Mol Endocrinol 2011, 25(6):969-979.
• [31]Giroux V, Bernatchez G, Carrier JC: Chemopreventive effect of ERbeta-Selective agonist on intestinal tumorigenesis in Apc(Min/+) mice. Mol Carcinog 2011, 50(5):359-369.
• [32]Papaxoinis K, Triantafyllou K, Sasco AJ, Nicolopoulou-Stamati P, Ladas SD: Subsite-specific differences of estrogen receptor beta expression in the normal colonic epithelium: implications for carcinogenesis and colorectal cancer epidemiology. Eur J Gastroenterol Hepatol 2010, 22(5):614-619.
• [33]Campbell-Thompson M, Lynch IJ, Bhardwaj B: Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer. Cancer Res 2001, 61(2):632-640.
• [34]Jassam N, Bell SM, Speirs V, Quirke P: Loss of expression of oestrogen receptor beta in colon cancer and its association with Dukes’ staging. Oncol Rep 2005, 14(1):17-21.
• [35]Konstantinopoulos PA, Kominea A, Vandoros G, Sykiotis GP, Andricopoulos P, Varakis I, Sotiropoulou-Bonikou G, Papavassiliou AG: Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour’s dedifferentiation. Eur J Cancer 2003, 39(9):1251-1258.
• [36]Ugai K, Nishimura K, Fukino K, Nakamura T, Ueno K: Functional analysis of transcriptional activity of cytosine and adenine (CA) repeats polymorphism in the estrogen receptor beta gene. J Toxicol Sci 2008, 33(2):237-240.
• [37]Gordon D, Finch SJ: Factors affecting statistical power in the detection of genetic association. J Clin Invest 2005, 115(6):1408-1418.